Journal article
No difference in the rate of change in telomere length or telomerase activity in HIV-Infected patients after three years of darunavir/Ritonavir with and without nucleoside analogues in the monet trial
A Solomon, S Tennakoon, E Leeansyah, J Arribas, A Hill, Y Van Delft, C Moecklinghoff, SR Lewin
Plos One | PUBLIC LIBRARY SCIENCE | Published : 2014
Abstract
Objective: To determine whether nucleos(t)ide reverse transcriptase inhibitors (NRTI) contribute to an accelerated loss in telomere length (TL) in HIV-infected patients on antiretroviral therapy (ART). Design: Substudy of randomised controlled trial. Methods: Patients with HIV RNA ,50 copies/mL on combination ART (n = 256) were randomised to darunavir/ritonavir (DRV/r) 800/100 mg once daily, either as monotherapy (n = 127) or with 2 NRTIs (n = 129) for up to 144 weeks. TL and telomerase activity was quantified on stored peripheral blood mononuclear cells (PBMC; n = 124) using quantitative real time PCR. Results: Patients in the sub-study had a mean age of 44 years and had received NRTI for a..
View full abstractGrants
Awarded by Janssen Biotech
Funding Acknowledgements
The authors AH, YVD, and CM received salary from Janssen to fund part of this study. SRL is supported by the National Health and Medical Research Council (NHMRC) of Australia Practitioner Fellowship [APP1042654] and the National Institutes for Health (NIH) [grant number 1R56AI095073-01A1 and U19 AI096109]. The funders contributed to the study design, data collection and analysis, decision to publish, and preparation of the manuscript.